DOSE DENSE HIGH DOSE METHYLPREDNISOLONE (HDMP) AND RITUXIMAB (RTX) ARE EFFECTIVE IN RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION (17P DEL) / TP53 MUTATION

被引：0
|
作者：
Pileckyte, R. [1 ]
Valceckiene, V. [1 ]
Zvirblis, T. [1 ]
Griskevicius, L. [1 ]
机构：
[1] Vilnius Univ Hosp Santariskiu Clin, Vilnius, Lithuania
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1294
引用
收藏
页码：525 / 526
页数：2
相关论文
共 50 条
  • [1] No benefit from adding rituximab to ibrutinib in relapsed or refractory chronic lymphocytic leukemia or 17p deletion/TP53 mutation
    Calleja, Anne
    HEMATOLOGIE, 2019, 25 (03): : 131 - 132
  • [2] DOSE DENSE HIGH DOSE METHYLPREDNISOLONE (HDMP) AND RITUXIMAB (RTX) ARE EFFECTIVE IN RELAPSED OR REFRACTORY HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Pileckyte, R.
    Jurgutis, M.
    Valceckiene, V.
    Stoskus, M.
    Gineikiene, E.
    Sejoniene, J.
    Degulys, A.
    Jakubauskas, A.
    Griskevicius, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 325 - 325
  • [3] Prognostic Impact of TP53 Mutation in Combination with Chromosome 17p Deletion in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Yun, Seongseok
    Sandoval-Sus, Jose
    Knepper, Todd C.
    Teer, Jamie
    Chavez, Julio C.
    Pinilla-Ibarz, Javier
    BLOOD, 2017, 130
  • [4] 17P deletion and TP53 gene mutation (17P/TP53) testing behaviour and treatment patterns for chronic lymphocytic leukemia (CLL) patients in France, Germany, Italy, Spain and UK (EU5)
    Canta, F. A. Bermudez
    Mitrofan, L.
    Karanis, Y. B.
    Mistry, H.
    Anger, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
    Tam, Constantine S.
    Stilgenbauer, Stephan
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 587 - 593
  • [6] Utilization of Targeted Exome Sequencing to Determine Implications of TP53 Mutation Status in Relation to 17p Deletion in Chronic Lymphocytic Leukemia (CLL)
    Chaudhury, Ateefa
    Chavez, Julio C.
    Pinilla-Ibarz, Javier
    BLOOD, 2014, 124 (21)
  • [7] Aberrant Nuclear p53 Expression Predicts Hemizygous 17p (TP53) Deletion in Chronic Lymphocytic Leukemia
    Chang, Hong
    Jiang, Allan M.
    Qi, Connie X. Y.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010, 133 (01) : 70 - 74
  • [8] Outcomes of first-line treatment for chronic lymphocytic leukemia (CLL) with 17p deletion (del17p)
    Strati, Paolo
    Keating, Michael J.
    O'Brien, Susan Mary
    Ferrajoli, Alessandra
    Burger, Jan Andreas
    Faderl, Stefan
    Jain, Nitin
    Wierda, William G.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Clinical Characteristics and Overall Survival Among Acute Myeloid Leukemia (AML) Patients with TP53 Gene Mutation (TP53m) or Chromosome 17p Deletion (17p del)
    Daver, Naval
    Iqbal, Shahed
    Huang, Julie
    Renard, Camille
    Lin, Joyce
    Pan, Harry
    Xing, Guan
    Pan, Yang
    Ramsingh, Giri
    BLOOD, 2022, 140 : 1445 - 1446
  • [10] Impact of TP53 mutation and 17p deletion in mantle cell lymphoma
    Halldorsdottir, A. M.
    Lundin, A.
    Murray, F.
    Mansouri, L.
    Knuutila, S.
    Sundstrom, C.
    Laurell, A.
    Ehrencrona, H.
    Sander, B.
    Rosenquist, R.
    LEUKEMIA, 2011, 25 (12) : 1904 - 1908
12345